2.6.1.2 (aminooxy)acetate - 42337 2.6.1.2 1,10-phenanthroline 2 mM, 51% inhibition 62 2.6.1.2 2-oxoglutarate substrate inhibition at neutral pH, not seen at pH 8.8 34 2.6.1.2 3-chloro-L-alanine 0.1 mM, 78% inhibition 3967 2.6.1.2 4-hydroxymercuribenzoate - 970 2.6.1.2 6-Azauracil 1.5 mM, 50% inhibition 5506 2.6.1.2 acarbose 0.1% acarbose fed to diabetic mice induces a decrease of the catalytic activity to 69.6% 412 2.6.1.2 Ag+ - 75 2.6.1.2 Al3+ - 264 2.6.1.2 Aminooxyacetate 0.0004 mM, 85% inhibition of mitochondrial alanine aminotransferase 1374 2.6.1.2 Aminooxyacetate 1 mM, complete inhibition 1374 2.6.1.2 Aminooxyacetate 2 mM, complete inhibition 1374 2.6.1.2 Aminooxyacetate 1 mM, 98% inhibition 1374 2.6.1.2 Aminooxyacetate competitive to L-alanine, uncompetitive to 2-oxoglutarate 1374 2.6.1.2 Aminooxyacetate complete inhibition, both isoforms 1374 2.6.1.2 aminooxyacetic acid 2.5 mM, complete inhibition 1554 2.6.1.2 beta-chloro-L-alanine - 1641 2.6.1.2 Cd2+ 0.1 mM, complete inhibition 52 2.6.1.2 Cd2+ 0.2 mM, 39% inhibition of alanine aminotransferase activity measured in soft body and gills, 0.6 mM, 46% inhibition 52 2.6.1.2 Citric acid - 1714 2.6.1.2 Co2+ - 23 2.6.1.2 Cu2+ reversed by L-cysteine and pyridoxal phosphate 19 2.6.1.2 Cu2+ inhibition of alanine aminotransferase activity in gills 19 2.6.1.2 cycloserine 1 mM, 10 mM, 50 mM, 10%, 52% and 100% inhibition respectively 2837 2.6.1.2 cycloserine 0.1 mM, 98% inhibition 2837 2.6.1.2 cycloserine - 2837 2.6.1.2 D-alanine competitive vs. L-alanine 164 2.6.1.2 DL-2-aminobutanoate - 213163 2.6.1.2 EDTA - 21 2.6.1.2 Fumaric acid - 6524 2.6.1.2 Glutarate 10 mM, 94% inhibition 545 2.6.1.2 Glutarate about 70% inhibition, both isoforms 545 2.6.1.2 Glutarate 2.5 mM, 69% inhibition 545 2.6.1.2 hesperidin - 2513 2.6.1.2 hesperitin - 241674 2.6.1.2 Hg2+ - 33 2.6.1.2 Hg2+ 93% inhibition 33 2.6.1.2 Hg2+ 0.1 mM, 81% inhibition 33 2.6.1.2 HgCl2 almost complete inhibition, both isoforms 110 2.6.1.2 HgCl2 2.5 mM, 96% inhibition 110 2.6.1.2 hydroxylamine activity recovered by pyridoxal 5'-phosphate 85 2.6.1.2 hydroxylamine - 85 2.6.1.2 hydroxylamine 1 mM, 96% inhibition 85 2.6.1.2 hydroxylamine 2 mM, 96% inhibition 85 2.6.1.2 hydroxylamine 2 mM, 73% inhibition 85 2.6.1.2 hydroxylamine complete inhibition, both isoforms 85 2.6.1.2 hydroxylamine 2.5 mM, complete inhibition 85 2.6.1.2 Isonicotinic hydrazide - 10678 2.6.1.2 KCN - 161 2.6.1.2 L-ascorbic acid 2 mM, 25% inhibition 974 2.6.1.2 L-Cycloserine - 1924 2.6.1.2 licorice traditional Chinese medicine, competitive, reversible 213164 2.6.1.2 malate 5 mM, 25% inhibition 283 2.6.1.2 Maleate about 70% inhibition, both isoforms 575 2.6.1.2 Maleate 2.5 mM, 70% inhibition 575 2.6.1.2 Maleic acid - 4029 2.6.1.2 additional information not inhibited by 6-azauridine or 6-azauridine 5'-phosphate 2 2.6.1.2 additional information not inhibited by EDTA, o-phenanthroline and L-ascorbate 2 2.6.1.2 o-phenanthroline weak 239 2.6.1.2 oxalic acid - 2093 2.6.1.2 p-chloromercuribenzoate reactivation by dithiothreitol 43 2.6.1.2 p-chloromercuribenzoate - 43 2.6.1.2 p-hydroxymercuribenzoate 1 mM, complete inhibition 98 2.6.1.2 p-hydroxymercuribenzoate 1 mM, 87% inhibition 98 2.6.1.2 p-hydroxymercuribenzoate 0.1 mM, 72% inhibition 98 2.6.1.2 p-hydroxymercuribenzoate complete inhibition, both isoforms 98 2.6.1.2 p-hydroxymercuribenzoate 2.5 mM, complete inhibition 98 2.6.1.2 Pb2+ reversed by L-cysteine and pyridoxal phosphate 139 2.6.1.2 Pb2+ 0.7 mM, 58% inhibition of alanine aminotransferase activity measured in soft body, 0.35 mM, 32% inhibition 139 2.6.1.2 Phenelzine monoamine oxidase inhibitor used as antidepressant/antipanic drug, maximum inhibition, i.e. 32%, of brain alanine aminotransferase at 15 mg/kg 5601 2.6.1.2 phenylhydrazine - 398 2.6.1.2 Qingkailing traditional Chinese medicine, noncompetitive, reversible 213165 2.6.1.2 Semicarbazide 1 mM, 40% inhibition 382 2.6.1.2 Semicarbazide 10 mM, 97% inhibition 382 2.6.1.2 succinate competitive inhibitor 58 2.6.1.2 succinic acid competitive, reversible 2759 2.6.1.2 vigabatrin structural analogue to gamma-amino butyric acid, anti-epilepsy drug, 1 mM, approx. 80% inhibition in vitro, in vivo alanine aminotransferase activity is reduced 30-40% 1-2h after administration 3140 2.6.1.2 Zn2+ - 14 2.6.1.2 Zn2+ 1 mM, 75% inhibition 14